Fulzerasib

Fulzerasib

Clinical data
Other names	Dupert; GFH-925; IBI-351
Legal status
Legal status	CN: ℞-only
Identifiers
IUPAC name (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-7,9-dimethyl-12-(4-methyl-2-propan-2-yl-3-pyridinyl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione
CAS Number	2641747-54-6
PubChem CID	167713279
IUPHAR/BPS	12393
DrugBank	DB21609
ChemSpider	129307087
UNII	6D5B7F245W
ChEBI	CHEBI:759169
ChEMBL	ChEMBL5314463
Chemical and physical data
Formula	C33H32ClFN6O4
Molar mass	631.11 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C4=C(C2=O)N(C(=O)[C@@]5(N4CCN(C5)C(=O)C=C)C)C)Cl)C6=C(C=CC=C6F)O
InChI InChI=InChI=1S/C33H32ClFN6O4/c1-7-23(43)39-13-14-40-28-19-15-20(34)26(24-21(35)9-8-10-22(24)42)37-30(19)41(27-18(4)11-12-36-25(27)17(2)3)31(44)29(28)38(6)32(45)33(40,5)16-39/h7-12,15,17,42H,1,13-14,16H2,2-6H3/t33-/m1/s1 Key:BRWVQEWFJJFLIQ-MGBGTMOVSA-N

Fulzerasib is a drug that is approved in China to treat KRAS G12C-positive non-small cell lung cancer (NSCLC).

Prior to marketing approval, fulzerasib had received two breakthrough therapy designations, the first for advanced G12C-mutant NSCLC and a second, for colorectal cancer (CRC) from the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration (NMPA).